ArticleThe oncologist2025

Economic and clinical outcomes among patients with cholangiocarcinoma receiving pemigatinib with or without history of cancer of unknown primary.

Sumit Verma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.